Literature DB >> 22345454

The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Melissa A Cobleigh1, Clinton Bradfield, Yuanjie Liu, Anand Mehta, Michael D Robek.   

Abstract

Vesicular stomatitis virus (VSV) is a highly cytopathic virus being developed as a vaccine vector due to its ability to induce strong protective T cell and antibody responses after a single dose. However, little is known regarding the mechanisms underlying the potent immune responses elicited by VSV. We previously generated a VSV vector expressing the hepatitis B virus middle envelope surface glycoprotein (MS) that induces strong MS-specific T cell and antibody responses in mice. After synthesis in the cytoplasm, the MS protein translocates to the endoplasmic reticulum, where it forms subviral particles that are secreted from the cell. To better understand the contributions of secreted and intracellular protein to the VSV-induced immune response, we produced a vector expressing a secretion-deficient MS mutant (MS(C69A)) and compared the immunogenicity of this vector to that of the wild-type VSV-MS vector in mice. As expected, the MS(C69A) protein was not secreted from VSV-infected cells and displayed enhanced proteasome-mediated degradation. Surprisingly, despite these differences in intracellular protein processing, the T cell and antibody responses generated to MS(C69A) were comparable to those elicited by virus expressing wild-type MS protein. Therefore, when it is expressed from VSV, the immune responses to MS are independent of particulate antigen secretion and the turnover rate of cytoplasmic protein. These results are consistent with a model in which the immune responses to VSV are strongly influenced by the replication cycle of the vector and demonstrate that characteristics of the vector have the capacity to affect vaccine efficacy more than do the properties of the antigen itself.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345454      PMCID: PMC3318607          DOI: 10.1128/JVI.05991-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses.

Authors:  S B Justin Wong; Christopher B Buck; Xuefei Shen; Robert F Siliciano
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

2.  Role of matrix protein in cytopathogenesis of vesicular stomatitis virus.

Authors:  D Blondel; G G Harmison; M Schubert
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes.

Authors:  S K Kundu; T C Merigan
Journal:  AIDS       Date:  1992-07       Impact factor: 4.177

4.  Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigen.

Authors:  Reinhold Schirmbeck; Waltraud Böhm; Nicolas Fissolo; Karl Melber; Jörg Reimann
Journal:  Eur J Immunol       Date:  2003-09       Impact factor: 5.532

5.  Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants.

Authors:  Reinhold Schirmbeck; Nektarios Dikopoulos; Marcin Kwissa; Frank Leithäuser; Kasper Lamberth; Soren Buus; Karl Melber; Jörg Reimann
Journal:  Eur J Immunol       Date:  2003-12       Impact factor: 5.532

6.  Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.

Authors:  Anjeanette Roberts; Jon D Reuter; Jean H Wilson; Stuart Baldwin; John K Rose
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.

Authors:  Jean Publicover; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo.

Authors:  B L Black; D S Lyles
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

Review 9.  Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases.

Authors:  Philip M McKenna; James P McGettigan; Roger J Pomerantz; Bernhard Dietzschold; Matthias J Schnell
Journal:  Curr HIV Res       Date:  2003-04       Impact factor: 1.581

Review 10.  Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Authors:  Gerd Sutter; Caroline Staib
Journal:  Curr Drug Targets Infect Disord       Date:  2003-09
View more
  10 in total

1.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

Review 3.  Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.

Authors:  Amanda N Pinski; Ilhem Messaoudi
Journal:  Curr Opin Virol       Date:  2021-11-05       Impact factor: 7.090

4.  Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.

Authors:  Eric Hastie; Dahlia M Besmer; Nirav R Shah; Andrea M Murphy; Megan Moerdyk-Schauwecker; Carlos Molestina; Lopamudra Das Roy; Jennifer M Curry; Pinku Mukherjee; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

5.  A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Authors:  Melissa A Cobleigh; Xin Wei; Michael D Robek
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

6.  VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

Authors:  Reinhard Tober; Zoltan Banki; Lisa Egerer; Alexander Muik; Sandra Behmüller; Florian Kreppel; Ute Greczmiel; Annette Oxenius; Dorothee von Laer; Janine Kimpel
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

7.  Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice.

Authors:  Jung-Eun Park; Hyun-Jin Shin
Journal:  Vet Q       Date:  2021-12       Impact factor: 3.320

8.  Cervico-Vaginal Inflammatory Cytokine and Chemokine Responses to Two Different SIV Immunogens.

Authors:  Nikki P L Toledo; Hongzhao Li; Robert W Omange; Tamara G Dacoba; Jose Crecente-Campo; Dane Schalk; Mohammad A Kashem; Eva Rakasz; Nancy Schultz-Darken; Qingsheng Li; James B Whitney; Maria J Alonso; Francis A Plummer; Ma Luo
Journal:  Front Immunol       Date:  2020-08-25       Impact factor: 7.561

9.  A Natural Botanical Product, Resveratrol, Effectively Suppresses Vesicular Stomatitis Virus Infection In Vitro.

Authors:  Shih-Chao Lin; Xiang Zhang; Caitlin W Lehman; Han-Chi Pan; Ya Wen; Shiow-Yi Chen
Journal:  Plants (Basel)       Date:  2021-06-17

10.  Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin.

Authors:  Robert C Mould; Jacob P van Vloten; Amanda W K AuYeung; Scott R Walsh; Jondavid de Jong; Leonardo Susta; Anthony J Mutsaers; James J Petrik; Geoffrey A Wood; Sarah K Wootton; Khalil Karimi; Byram W Bridle
Journal:  Cancers (Basel)       Date:  2021-12-14       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.